Thyroid Nodules — Evaluation, TIRADS Classification, FNAC & Management — Symptoms, Causes & Treatment | MyMedicPlus

Thyroid nodules are discrete lesions within the thyroid gland — detectable by ultrasound, physical examination, or incidentally on imaging studies performed for other reasons (CT, MRI, PET-CT). They are extremely common — detectable by high-frequency ultrasound in 50-70% of the adult general population; autopsy studies consistently identify thyroid nodules in 30-50% of subjects without any known thyroid disease. The prevalence increases with age, female sex, iodine deficiency, and a history of radiation exposure. The critical clinical challenge of thyroid nodules is identifying the approximately 5-10% that are malignant — requiring further investigation and treatment — from the vast majority that are benign (colloid cysts, hyperplastic nodules, follicular adenomas) and require only monitoring. The widespread adoption of neck ultrasonography has dramatically increased incidental detection of thyroid nodules ('incidentalomas') — the majority of these are clinically insignificant. Effective management requires structured risk stratification using validated ultrasound scoring systems (ACR TIRADS, ATA, BTA guidelines) to guide selective biopsy — avoiding unnecessary procedures for clearly benign nodules, while ensuring timely evaluation of potentially malignant lesions. The great majority of thyroid nodules — even those requiring biopsy — will have benign cytology and can be managed with ultrasound surveillance rather than surgery. Modern management of thyroid nodules has moved away from 'biopsy all nodules' towards risk-stratified selective biopsy — a significant improvement in patient experience and system efficiency.

Most thyroid nodules are benign — causes include: Colloid cyst (the most common benign thyroid nodule): accumulation of colloid (the protein-rich fluid stored in thyroid follicles) within a cystic space — typically appears as a cyst with internal echogenic foci (colloid crystals — 'comet-tail' artefact on ultrasound) and is almost always benign; may enlarge and become symptomatic. Hyperplastic (or adenomatoid) nodule: focal overgrowth of normal thyroid follicular tissue — part of a multinodular goitre; often multiple; non-neoplastic; very low malignancy risk. Follicular adenoma: a benign encapsulated follicular cell neoplasm — cannot be reliably distinguished from follicular carcinoma on FNAC cytology (both Bethesda IV 'follicular neoplasm') — requires hemithyroidectomy and histological capsular invasion assessment to exclude malignancy. Hashimoto's thyroiditis (autoimmune thyroiditis): produces a heterogeneous, lobulated gland that may contain multiple pseudo-nodules — background of hypoechoic parenchyma from lymphocytic infiltration; associated with slightly increased papillary thyroid cancer risk; TSH is typically elevated or at high-normal. Autonomously functioning thyroid nodule (AFTN — 'hot nodule'): produces thyroid hormone independently of TSH stimulation — causes thyrotoxicosis (low TSH, elevated fT4/T3); almost never malignant (TSH suppression reduces cancer risk — proliferative stimulus removed); treated with radioiodine (most effective) or thyroidectomy. Toxic multinodular goitre (TMNG): multiple autonomously functioning nodules causing subclinical or overt thyrotoxicosis — the most common cause of hyperthyroidism in elderly patients and in iodine-deficient areas. Cystic lesions: purely cystic lesions (completely anechoic with posterior acoustic enhancement — thin-walled) are almost always benign; complex cystic nodules with solid components require evaluation. Malignant thyroid nodules: as discussed in the thyroid cancer profile — predominantly papillary thyroid cancer (PTC), follicular thyroid cancer, medullary thyroid cancer, and rarely anaplastic thyroid cancer; thyroid metastases from other primary cancers (renal cell carcinoma — the most common metastasis to the thyroid; melanoma; lung). Risk factors for a thyroid nodule being malignant: childhood radiation exposure; personal or family history of thyroid cancer; RET, PTEN, or APC germline mutations; male sex; extremes of age (children and elderly above 70); rapid growth; single rather than multiple nodules (though cancer occurs in multinodular goitres); firm, hard, or fixed consistency on palpation; associated cervical lymphadenopathy; hoarseness.

The majority of thyroid nodules are asymptomatic and are discovered incidentally — on neck ultrasound performed for other reasons (carotid artery assessment, parathyroid imaging), on CT or MRI of the neck or chest, or as a visible or palpable neck lump noticed by the patient or during a routine examination. Visible or palpable neck lump: felt as a discrete swelling or lump at the base of the front of the neck; characteristically moves upwards on swallowing (the thyroid gland is invested in the pre-tracheal fascia and moves with the larynx and trachea during swallowing — a key clinical sign distinguishing thyroid from other neck masses); may be noticed by the patient or their partner; cosmetic concern for large visible goitres. Compressive symptoms (from large nodules or multinodular goitre): dysphagia (difficulty swallowing — from oesophageal compression by a posterior goitre); choking sensation or a feeling of a lump in the throat (globus sensation); stridor or respiratory difficulty (from tracheal compression or intrathoracic extension of the goitre into the superior mediastinum — Pemberton's sign: facial plethora and venous congestion of the head and neck when the arms are elevated above the head — indicating superior vena cava compromise from a substernal goitre). Hoarseness of voice: requires urgent evaluation — suggests recurrent laryngeal nerve involvement from a malignant thyroid nodule compressing or invading the nerve (urgent laryngoscopy and thyroid ultrasound indicated). Symptoms of hyperthyroidism (from autonomously functioning nodule — 'hot nodule'): palpitations, anxiety, weight loss despite good appetite, heat intolerance, sweating, diarrhoea, tremor, insomnia — from excess thyroid hormone production; suppressed TSH on blood tests. Symptoms of hypothyroidism (from Hashimoto's thyroiditis with goitre): fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, bradycardia, menorrhagia — elevated TSH. Pain in a thyroid nodule: usually indicates haemorrhage into a colloid cyst or hyperplastic nodule — sudden onset of pain in the neck with a rapidly enlarging tender mass; resolves over days to weeks; subacute (De Quervain's) thyroiditis also causes thyroid pain (fever, raised ESR, elevated CRP) with initial hyperthyroidism then hypothyroidism.

Thyroid function tests (TSH, fT4, fT3): the first-line blood test for all patients with a thyroid nodule — a suppressed TSH suggests an autonomously functioning (hot) nodule that is almost never malignant and warrants radionuclide scan rather than FNAC; a normal or elevated TSH does not exclude malignancy. Thyroid antibodies: anti-TPO (anti-thyroid peroxidase) and anti-TG (anti-thyroglobulin) antibodies — elevated in Hashimoto's thyroiditis. Thyroid ultrasound (the essential investigation for all thyroid nodules): high-frequency (7.5-15 MHz linear) ultrasound characterises each nodule for sonographic features that stratify malignancy risk. ACR TIRADS (Thyroid Imaging Reporting and Data System — 2017): the most widely used risk stratification system — assigns points for specific sonographic features: composition (cystic or almost cystic: 0 points; spongiform: 0; mixed cystic and solid: 1; solid or almost solid: 2); echogenicity (anechoic: 0; hyperechoic or isoechoic: 1; hypoechoic: 2; very hypoechoic: 3); shape (wider than tall: 0; taller than wide: 3 — the single highest-risk feature); margin (smooth: 0; ill-defined: 0; lobulated or irregular: 2; extra-thyroidal extension: 3); echogenic foci (none or large comet-tail artefact: 0; macrocalcifications: 1; peripheral/egg-shell calcifications: 2; punctate echogenic foci/microcalcifications: 3). Total score gives TIRADS category: TR1 (benign — 0 points; no FNA); TR2 (not suspicious — 2; no FNA); TR3 (mildly suspicious — 3; FNA if above 2.5 cm; follow if above 1.5 cm); TR4 (moderately suspicious — 4-6; FNA if above 1.5 cm; follow if above 1 cm); TR5 (highly suspicious — 7+; FNA if above 1 cm; follow if above 0.5 cm). Ultrasound-guided fine-needle aspiration cytology (FNAC — US-FNAC): the key diagnostic test for nodules meeting biopsy criteria — 22-25 gauge needle; 2-5 passes with rapid on-site evaluation (ROSE) where available to check sample adequacy; Bethesda Reporting System classifies cytology: Bethesda I (non-diagnostic — inadequate cellularity: 1-4% malignancy; repeat FNAC); Bethesda II (benign — follicular nodule, colloid cyst, Hashimoto's: 0-3% malignancy; ultrasound surveillance — every 1-2 years for 5 years); Bethesda III (atypia of undetermined significance/AUS: 5-15% malignancy; repeat FNAC or molecular testing); Bethesda IV (follicular neoplasm: 15-30% malignancy; diagnostic hemithyroidectomy); Bethesda V (suspicious for malignancy: 60-75% malignancy; total thyroidectomy); Bethesda VI (malignant: >97% malignancy; total thyroidectomy). Molecular testing for indeterminate nodules (Bethesda III-IV): ThyroSeq v3 (molecular sequencing of thyroid cancer mutations — NPV for cancer in Bethesda III is approximately 96%); Afirma Gene Sequencing Classifier (gene expression panel — 'benign' result has NPV approximately 94-96%); these tests substantially reduce unnecessary diagnostic surgery for indeterminate nodules — increasingly adopted in the UK and widely used in the USA. Radionuclide (technetium-99m or iodine-123) thyroid scintigraphy: reserved for patients with low or suppressed TSH — identifies 'hot' (autonomously functioning — benign) vs. 'cold' (non-functioning — higher malignancy risk) nodules; no role in TSH-normal patients.

The management approach is determined by the biopsy result, nodule size, and thyroid function: Benign thyroid nodules (Bethesda II): no surgery required — ultrasound surveillance (every 12-24 months for the first 5 years, then every 3-5 years if stable); reassure the patient that surgery is not needed. Nodule growth above 20% in two dimensions on surveillance warrants repeat FNAC. Active surveillance for low-risk papillary thyroid microcarcinoma: for unifocal papillary carcinomas below 10 mm with no high-risk features (no extrathyroidal extension, no lymph node metastases, no worrisome sonographic features, no patient anxiety about non-surgical management) — active surveillance with ultrasound every 6-12 months and deferral of surgery is increasingly accepted as an alternative to immediate surgery; Japanese landmark studies (Ito et al.) with up to 20 years of follow-up demonstrate that the majority of microcarcinomas do not grow significantly, and delayed surgery after growth or lymph node development does not compromise cure; the ATA 2015 guidelines support active surveillance as an alternative in appropriate patients and at experienced centres; surgery is offered if growth above 3 mm, lymph node metastases develop, or the patient prefers surgery. Surgery (thyroidectomy): indications include: confirmed or highly suspicious malignancy (Bethesda V-VI); follicular neoplasm (Bethesda IV) — hemithyroidectomy (isthmus included) followed by histology — converts to total thyroidectomy if malignant; compressive symptoms (dysphagia, stridor, difficulty breathing) from large nodule or substernal goitre; cosmetic concern from significantly enlarged goitre; patient preference after full counselling. Total thyroidectomy for confirmed malignancy. Hemithyroidectomy for Bethesda IV (diagnostic) and for low-risk unilateral thyroid cancer (appropriate staging). Autonomously functioning nodule (hot nodule) causing thyrotoxicosis or significant hyperthyroidism risk: radioiodine I-131 therapy (the most effective — ablates the hot nodule; normal thyroid function preserved in majority if single AFTN; hypothyroidism risk approximately 20-30% at 10 years — due to radiation to adjacent normal tissue); thyroidectomy (for large nodules, concurrent suspicious cold nodule in the same gland, patient preference, or when rapid control of thyrotoxicosis is needed); anti-thyroid drug (carbimazole) — controls hyperthyroidism but does not cure the underlying nodule — used as bridging therapy before definitive treatment. Ultrasound-guided thermal ablation (radiofrequency ablation — RFA, microwave ablation — MWA, laser ablation): increasingly available for benign symptomatic thyroid nodules in patients who decline or are unfit for surgery; achieves approximately 50-70% volume reduction; NICE approved RFA as an option (IPG714); considered for autonomously functioning nodules as an alternative to radioiodine or surgery in selected patients.

Haemorrhage into a thyroid nodule: sudden haemorrhage into a colloid cyst or degenerated hyperplastic nodule — sudden onset of neck pain, rapid enlargement of the thyroid, and local compressive discomfort; usually self-limiting; may require aspiration if causing significant compressive symptoms; rarely (with very large nodule haemorrhage into a critically positioned neck) can cause airway compromise. Compressive complications from large nodules or multinodular goitre: tracheal deviation and compression (tracheal narrowing below 8-10 mm requires surgical evaluation); oesophageal compression causing dysphagia; superior vena cava obstruction from substernal goitre (Pemberton's sign — facial plethora and venous engorgement on arm elevation); unilateral or bilateral recurrent laryngeal nerve compression (rare from benign disease but occurs with large nodules — hoarseness). Hyperthyroidism from autonomously functioning nodule: subclinical hyperthyroidism (suppressed TSH with normal fT4/T3) — associated with increased risk of atrial fibrillation (3-fold elevated risk) and accelerated bone loss (particularly in post-menopausal women); overt hyperthyroidism — atrial fibrillation, osteoporosis, cardiovascular consequences. Malignant transformation: for benign nodules — a theoretical concern but very low absolute risk for most benign categories; follicular adenomas carry the relevant diagnostic uncertainty (Bethesda IV — 15-30% malignancy risk on final histology); long-term surveillance addresses this concern. Anxiety and psychological burden: detection of a thyroid nodule — even a clearly benign one — can cause significant anxiety about cancer; clear, evidence-based communication about the very low absolute malignancy risk of most ultrasound-detected nodules is essential; the vast majority of thyroid nodules are benign and do not affect quality of life or lifespan. Complications of unnecessary surgery: performing thyroidectomy for clearly benign nodules exposes patients to unnecessary surgical risks (RLN injury with hoarseness in 1-2% permanently; hypoparathyroidism in 1-2% permanently) — the rationale for structured risk stratification and selective FNAC is to avoid these harms.

Adequate iodine intake: iodine is essential for thyroid hormone synthesis; iodine deficiency promotes goitre formation and is associated with increased follicular thyroid cancer risk; adequate dietary iodine (recommended daily intake 150 micrograms for adults; 250 micrograms in pregnancy) from iodised salt, dairy products, and seafood prevents iodine deficiency-related thyroid nodular disease. Avoidance of unnecessary neck radiation: minimise unnecessary CT scans to the neck region — particularly in children and adolescents (radiation exposure increases thyroid cancer risk); modern CT protocols use appropriate radiation reduction techniques. Radiation emergency preparedness: potassium iodide (KI) tablets should be taken within hours of a nuclear accident involving I-131 release (as recommended by government emergency protocols); saturating the thyroid with stable iodine prevents uptake of radioactive I-131 — highly effective if taken promptly. Incidentaloma management — avoiding over-investigation: not every incidentally detected thyroid nodule requires FNAC; structured ultrasound risk stratification (ACR TIRADS) avoids unnecessary biopsy of nodules that are clearly benign on imaging; GP awareness of current guidelines (BTA 2014 guidelines, updated 2023) prevents inappropriate referral burden and patient anxiety. Reassurance of benign disease: patients with Bethesda II FNAC (benign) or TIRADS 1-2 nodules should receive clear communication: 'This nodule is almost certainly benign — you do not need surgery, and monitoring with an ultrasound scan every 1-2 years is all that is required'; surveys consistently show that patients with 'no action needed' nodules experience significant anxiety when told they have a thyroid nodule without adequate contextual reassurance. Patients with relevant family history: first-degree relatives of patients with medullary thyroid cancer should have serum calcitonin testing and germline RET mutation screening; relatives of patients with hereditary thyroid cancer syndromes (Cowden, FAP) should be enrolled in appropriate surveillance protocols.

See a GP within 2 weeks (urgent referral) for: any new palpable neck lump (particularly if firm, hard, or rapidly growing); a thyroid lump with associated hoarseness of voice (possible recurrent laryngeal nerve compression by a malignant nodule — urgent laryngoscopy and ultrasound needed); thyroid lump with associated cervical lymphadenopathy (possible malignant disease); and palpable goitre with swallowing difficulty or noisy breathing (stridor). An incidentally discovered thyroid nodule on CT or MRI of the neck or chest (report will often note a thyroid nodule): follow up the radiology report with your GP — most will require an ultrasound assessment and may need FNAC based on the features; do not ignore incidental thyroid nodule reports. Go to A&E immediately for: sudden severe neck pain and rapid enlargement of a thyroid nodule (haemorrhage into a cyst — rarely causes airway compromise); stridor or progressive difficulty breathing associated with a large thyroid mass. For patients already under surveillance for a known benign thyroid nodule: contact GP or endocrinologist if you notice: rapid growth of the nodule (visible increase in size over weeks to months); new or worsening swallowing difficulty or breathing difficulty; hoarseness; or new palpable lymph nodes in the neck. Patients with autonomously functioning nodules causing hyperthyroidism: contact your endocrinologist urgently if developing palpitations, chest pain, or signs of fast atrial fibrillation — the cardiovascular consequences of untreated thyrotoxicosis can be serious.